$NTRA
Natera, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022012331 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $210.6M $198.2M $194.1M
YoY Change 33.22% 39.55% 27.45%
Cost Of Revenue $116.5M $109.2M $103.2M
YoY Change 43.19% 43.52% 54.51%
Gross Profit $94.13M $88.96M $90.92M
YoY Change 22.65% 34.97% 6.34%
Gross Profit Margin 44.69% 44.89% 46.83%
Selling, General & Admin $147.7M $149.5M $147.6M
YoY Change 14.93% 17.27% 36.28%
% of Gross Profit 156.88% 168.01% 162.38%
Research & Development $65.51M $82.58M $80.41M
YoY Change -33.46% 53.63% 100.09%
% of Gross Profit 69.6% 92.83% 88.45%
Depreciation & Amortization $5.141M $4.629M $3.002M
YoY Change 71.54% 70.69% 17.77%
% of Gross Profit 5.46% 5.2% 3.3%
Operating Expenses $213.2M $232.0M $228.0M
YoY Change -6.07% 28.06% 53.55%
Operating Profit -$119.1M -$143.1M -$137.1M
YoY Change -20.74% 24.1% 117.61%
Interest Expense $2.330M $2.150M $2.087M
YoY Change 12.13% 3.61% 0.68%
% of Operating Profit
Other Income/Expense, Net $87.00K $277.0K $801.0K
YoY Change -93.17% -82.52% -42.79%
Pretax Income -$121.3M -$145.0M -$138.4M
YoY Change -19.67% 25.2% 117.23%
Income Tax $185.0K $193.0K $179.0K
% Of Pretax Income
Net Earnings -$121.5M -$145.2M -$138.6M
YoY Change -19.69% 25.1% 117.06%
Net Earnings / Revenue -57.67% -73.23% -71.39%
Basic Earnings Per Share -$1.25 -$1.50 -$1.45
Diluted Earnings Per Share -$1.25 -$1.50 -$1.45
COMMON SHARES
Basic Shares Outstanding 96.96M 96.58M 95.58M
Diluted Shares Outstanding 97.05M 96.58M 95.58M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $521.2M $638.7M $752.0M
YoY Change -49.09% 10.07% 15.05%
Cash & Equivalents $57.04M $91.30M $158.3M
Short-Term Investments $464.1M $547.4M $593.7M
Other Short-Term Assets $31.69M $24.13M $35.36M
YoY Change 8.94% -22.44% 32.92%
Inventory $40.43M $30.47M $25.05M
Prepaid Expenses
Receivables $236.4M $208.3M $167.9M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $829.6M $901.6M $980.2M
YoY Change -30.35% 21.85% 23.86%
LONG-TERM ASSETS
Property, Plant & Equipment $87.49M $81.77M $78.36M
YoY Change 47.55% 67.28% 95.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.21M $21.50M $21.68M
YoY Change 37.9% 67.37% 74.72%
Total Long-Term Assets $179.5M $165.4M $164.4M
YoY Change 49.38% 50.29% 61.04%
TOTAL ASSETS
Total Short-Term Assets $829.6M $901.6M $980.2M
Total Long-Term Assets $179.5M $165.4M $164.4M
Total Assets $1.009B $1.067B $1.145B
YoY Change -23.05% 25.53% 28.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.23M $28.19M $18.07M
YoY Change 318.35% 38.83% 285.95%
Accrued Expenses $157.0M $139.6M $130.9M
YoY Change 62.76% 62.01% 69.37%
Deferred Revenue $7.932M $16.01M $13.91M
YoY Change -17.95% 50.36% 53.42%
Short-Term Debt $50.10M $50.10M $50.10M
YoY Change 0.2% 0.2% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $267.3M $251.6M $231.1M
YoY Change 33.83% 27.09% 38.39%
LONG-TERM LIABILITIES
Long-Term Debt $281.3M $281.0M $280.7M
YoY Change 0.45% 0.44% 0.43%
Other Long-Term Liabilities $98.87M $3.618M $2.531M
YoY Change 6653.69% -95.05% -96.61%
Total Long-Term Liabilities $380.2M $3.618M $2.531M
YoY Change 25870.63% -98.97% -99.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $267.3M $251.6M $231.1M
Total Long-Term Liabilities $380.2M $3.618M $2.531M
Total Liabilities $647.5M $622.4M $602.3M
YoY Change 17.22% 12.99% 15.6%
SHAREHOLDERS EQUITY
Retained Earnings -$1.800B -$1.700B -$1.500B
YoY Change 38.46% 54.55% 51.98%
Common Stock $2.181B $2.140B $2.090B
YoY Change 8.43% 52.86% 54.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $361.6M $444.6M $542.3M
YoY Change
Total Liabilities & Shareholders Equity $1.009B $1.067B $1.145B
YoY Change -23.05% 25.53% 28.11%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$121.5M -$145.2M -$138.6M
YoY Change -19.69% 25.1% 117.06%
Depreciation, Depletion And Amortization $5.141M $4.629M $3.002M
YoY Change 71.54% 70.69% 17.77%
Cash From Operating Activities -$102.2M -$110.8M -$137.3M
YoY Change 12.29% 57.1% 83.34%
INVESTING ACTIVITIES
Capital Expenditures -$12.21M -$7.776M $15.89M
YoY Change -29.86% -9.91% 54.82%
Acquisitions
YoY Change
Other Investing Activities $78.81M $42.57M $222.9M
YoY Change -119.04% -37.95% 129.81%
Cash From Investing Activities $66.60M $34.79M $207.0M
YoY Change -115.44% -41.99% 138.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.393M 8.918M 4.156M
YoY Change -99.75% 6.88% -9.06%
NET CHANGE
Cash From Operating Activities -102.2M -110.8M -137.3M
Cash From Investing Activities 66.60M 34.79M 207.0M
Cash From Financing Activities 1.393M 8.918M 4.156M
Net Change In Cash -34.26M -67.14M 73.91M
YoY Change -206.08% 2889.4% 349.75%
FREE CASH FLOW
Cash From Operating Activities -$102.2M -$110.8M -$137.3M
Capital Expenditures -$12.21M -$7.776M $15.89M
Free Cash Flow -$90.04M -$103.1M -$153.2M
YoY Change 22.25% 66.44% 79.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96579000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88077000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96081000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87387000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96903000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95140000
dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604821
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96579000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88077000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96081000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87387000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M20D
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity File Number
EntityFileNumber
001-37478
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91298000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-179503000
dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
249-9090
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTRA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96957360
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84386000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
86000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
228000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
547353000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
829896000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3561000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2429000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
208312000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
122074000
CY2022Q2 us-gaap Inventory Net
InventoryNet
30465000
CY2021Q4 us-gaap Inventory Net
InventoryNet
26909000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24041000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29645000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
901555000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1093138000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81772000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65516000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62147000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59013000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21502000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18820000
CY2022Q2 us-gaap Assets
Assets
1066976000
CY2021Q4 us-gaap Assets
Assets
1236487000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
28192000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27206000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
32959000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
40941000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
124372000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
93353000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16009000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7404000
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
50086000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
50052000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
251618000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
218956000
CY2022Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
281020000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
193000
CY2021Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
280394000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20721000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3618000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1479000
CY2022Q2 us-gaap Liabilities
Liabilities
622394000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21318000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
65417000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61036000
CY2021Q4 us-gaap Liabilities
Liabilities
583183000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96903000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95140000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2139551000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2050417000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1678582000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1394836000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16397000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2287000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
444582000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
653304000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1066976000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1236487000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
198200000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142026000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
392333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294342000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82580000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53752000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
162994000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93940000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149468000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
127456000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
297102000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
235788000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
341285000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
257320000
us-gaap Costs And Expenses
CostsAndExpenses
672548000
us-gaap Costs And Expenses
CostsAndExpenses
472653000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-143085000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-115294000
us-gaap Operating Income Loss
OperatingIncomeLoss
-280215000
us-gaap Operating Income Loss
OperatingIncomeLoss
-178311000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2150000
CY2021Q2 us-gaap Interest Expense
InterestExpense
2075000
us-gaap Interest Expense
InterestExpense
4237000
us-gaap Interest Expense
InterestExpense
4148000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
277000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1585000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-147644000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116782000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1078000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2956000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-144958000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-115784000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-283374000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-756000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
372000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
376000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7631000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-297856000
us-gaap Net Income Loss
NetIncomeLoss
-179879000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2493000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-14110000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1818000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-145151000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-116026000
us-gaap Net Income Loss
NetIncomeLoss
-283746000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181697000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96579000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88077000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96081000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87387000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
372445000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2259000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6085000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35103000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-756000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-116026000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
299110000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
486236000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6829000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6085000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58335000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-1818000
ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-76678000
us-gaap Net Income Loss
NetIncomeLoss
-179879000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
299110000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
542335000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8496000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40973000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-2493000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-145151000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
444582000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
653304000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4578000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8496000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76060000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-14110000
us-gaap Net Income Loss
NetIncomeLoss
-283746000
ntra Inventory Reserve Adjustments
InventoryReserveAdjustments
612000
ntra Other Non Cash Benefits Charges
OtherNonCashBenefitsCharges
39000
ntra Other Non Cash Benefits Charges
OtherNonCashBenefitsCharges
117000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
444582000
us-gaap Profit Loss
ProfitLoss
-283746000
us-gaap Profit Loss
ProfitLoss
-179879000
us-gaap Operating Lease Cost
OperatingLeaseCost
6652000
us-gaap Operating Lease Cost
OperatingLeaseCost
5357000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5262000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
2960000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
3790000
us-gaap Share Based Compensation
ShareBasedCompensation
76060000
us-gaap Share Based Compensation
ShareBasedCompensation
58335000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
625000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
610000
ntra Inventory Reserve Adjustments
InventoryReserveAdjustments
181000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
1501000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
63000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-203000
us-gaap Gain Loss On Investments
GainLossOnInvestments
35000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
87738000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21628000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3737000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8991000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4727000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2497000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2492000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12313000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7982000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
471000
us-gaap Operating Lease Payments
OperatingLeasePayments
5528000
us-gaap Operating Lease Payments
OperatingLeasePayments
4992000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
29525000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
24374000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8009000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-38721000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-248126000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-145439000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
79956000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
71054000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
191939000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
31144000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
153500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
205510000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23661000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18891000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
241822000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
146709000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4578000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6829000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8496000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
6085000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13074000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12914000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6770000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14184000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84614000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48855000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2035000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4688000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91384000
CY2021Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
4110000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63039000
us-gaap Interest Paid Net
InterestPaidNet
3612000
us-gaap Interest Paid Net
InterestPaidNet
3538000
us-gaap Net Income Loss
NetIncomeLoss
-283700000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1700000000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91400000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
547400000
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
50100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The preparation of financial statements in accordance with generally accepted accounting principles (“GAAP”) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, average selling price expected to be received from insurance payors, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The total consideration which the Company expects to be entitled to from patients and insurance carriers in exchange for the Company's products is a significant estimate determined by calculating the average selling price based on the contractual pricing agreed to with each insurance carrier for each test (CPT code) performed adjusted for variable consideration related to historical percent of cases allowed, historical percent of patient responsibility collected, and historical percent of contract price collected from insurance carriers. The Company uses the expected-value approach of estimating variable consideration.  The Company also considers recent trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or insurance coverages.  For insurance carriers with similar reimbursement characteristics, the Company uses a portfolio approach to estimate the effects of variable consideration. The Company also applies a constraint to the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue may occur in future periods.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">When assessing the total consideration for insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Stock-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”), performance-based awards, market-based awards, and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Stock based compensation granted to the Company’s employees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period or estimated performance period of the respective awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options issued to employees and non-employees. Stock-based compensation expense for stock-based awards is based on their grant date fair value. The fair value of stock option awards is generally recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are estimated based on historical trends at the time of grant and revised as necessary for service-based grants. If awards have both a service condition and performance or market condition, then an accelerated expense method is used. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, we calculate the expected term using the simplified method for “plain vanilla” stock option awards. The Company determines expected volatility using the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company determines the fair value of RSUs based on the closing price of our stock price, which is listed on Nasdaq, at the date of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For stock options and performance-based awards that vest upon meeting performance conditions or market conditions in combination with performance conditions, the Company derives the requisite service period from the grant date to the date it is probable that the vesting conditions will be met. The requisite service period is considered to be a significant accounting estimate. For stock options with market conditions, the Company derives the requisite service period using the Monte Carlo simulation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Monte Carlo simulation model is used to estimate the fair value of market-based condition awards. The model requires the input of the Company's expected stock price and peer stock price volatility, the expected term of the awards, and a risk-free interest rate. Determining these assumptions requires significant judgment. See further discussion on the valuation assumptions used under Note 9, <i style="font-style:italic;">Stock Based Compensation</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Income taxes are recorded in accordance with Financial Accounting Standards Board ASC Topic 740,<i style="font-style:italic;"> Income </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Taxes </i>("ASC 740"), which provides for deferred taxes using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. See further discussion in Note 11, <i style="font-style:italic;">Income Taxes</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Allowance for doubtful accounts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The allowance for doubtful accounts for trade accounts receivable and other receivables is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company’s inventory balance primarily consists of raw materials and supplies. Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products. However, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Investments and financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Right-of-use assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The incremental borrowing rate is used to determine the present value of the minimum future lease payments. The Company estimates the incremental borrowing rate of its leases based on the weighted-average annual percentage yield of corporate bonds with a similar credit rating as the Company and a similar bond term as the lease term as of the approximate lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Property and equipment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Property and equipment, including purchased and internally developed software, are stated at cost. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are generally three to five years determined by the classification of the property and equipment class in accordance with the Company’s fixed asset policy. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the useful lives assigned to property and equipment placed in service in accordance with the Company’s fixed asset policy and changes the estimates of useful lives to reflect the results of such reviews. The Company amortizes its internal-use software over the estimated useful lives of three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other accrued liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company's uses estimates, judgments, and assumptions in several areas including, but not limited to, estimates of progress to date for certain contracts with vendors, liabilities related to clinical trials, payroll and related expenses, marketing liabilities, reserves associated with insurance and general overpayments, tax-related liabilities, and other operating expenses. Estimates consist of historical trends, analytical procedures, review of supporting documentation, inquiries with supply partners and vendors, and other relevant assumptions. Although the Company believe its estimates, assumptions, and judgment are reasonable, it is based upon information presently available and are subject to change.</p>
CY2022Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2392000
CY2021Q2 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
385000
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3561000
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
495000
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3561000
CY2022Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1170000
CY2021Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-63000
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
1000
CY2021Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3788000
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2429000
CY2020Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
4220000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1501000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-63000
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
369000
CY2021Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3788000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, and the full extent and duration of the impact of the COVID 19 pandemic on our business, our operations, and the global economy as a whole is not yet known. While the Company’s test volumes and overall average selling prices increased in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, the Company cannot predict the potential nature, magnitude and duration of the effects of the COVID-19 pandemic on the macroeconomic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, in our operations as a public company, prolonged government disruptions, global pandemics and other natural disasters or geopolitical actions, for example the geopolitical instability due to the ongoing military conflict between Russia and Ukraine, have resulted in significant economic uncertainty. These macroeconomic conditions could affect our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of financial conditions for insurance carriers, patients, clinics and laboratory partners and generally does not require collateral to support credit sales. For the three and six months ended June 30, 2022, and 2021, there were no customers exceeding 10% of total revenues on an individual basis. As of June 30, 2022 and December 31, 2021, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p>
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-1209000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13904000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3197000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2287000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4259000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16397000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2441000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16397000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2441000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
198200000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142026000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
392333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294342000
CY2022Q2 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
587621000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-30839000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
198200000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
142026000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
392333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
294342000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
208312000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
122074000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16009000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7404000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20721000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21318000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36730000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28722000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28722000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
72930000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
14974000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3474000
ntra Contract With Customer Liability Refunds Of Revenues Previously Deferred
ContractWithCustomerLiabilityRefundsOfRevenuesPreviouslyDeferred
10000000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-5757000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
603806000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16185000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-1356000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36730000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34209000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-5800000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
842224000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1342000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3629000
CY2021Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
839937000
CY2022Q2 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
587621000
CY2021Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
839937000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
191900000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
200000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
70
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
187392000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
184947000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
376146000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
362406000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
563538000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
547353000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
108329000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19413000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81772000
CY2022Q2 ntra Accrued Interest
AccruedInterest
1078000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
84929000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26557000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65516000
us-gaap Depreciation
Depreciation
7300000
us-gaap Depreciation
Depreciation
5300000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2930000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2567000
CY2022Q2 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
12454000
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
15726000
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
11324000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
15854000
CY2022Q2 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
6251000
CY2021Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
6794000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
32959000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
40941000
CY2022Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
15912000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17210000
CY2022Q2 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
23142000
CY2021Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
5849000
CY2022Q2 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
13997000
CY2021Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
3799000
CY2022Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
6449000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
7853000
CY2022Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
21374000
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
11758000
CY2022Q2 ntra Accrued Shipping Charges
AccruedShippingCharges
2157000
CY2021Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
969000
CY2022Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1857000
CY2021Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
2230000
CY2022Q2 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
1354000
CY2021Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
13442000
CY2022Q2 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
21166000
CY2021Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
11218000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5636000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5752000
CY2021Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2022Q2 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
5608000
CY2021Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1853000
CY2022Q2 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
4642000
CY2021Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
10342000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
124372000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
93353000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17210000
CY2020Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17366000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
8576000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
10960000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
6491000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
3054000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
3383000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
2971000
CY2022Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
15912000
CY2021Q2 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
22301000
ntra Noncash Investing Activities Related To Right Of Use Assets
NoncashInvestingActivitiesRelatedToRightOfUseAssets
7500000
ntra Noncash Investing Activities Related To Right Of Use Assets
NoncashInvestingActivitiesRelatedToRightOfUseAssets
30100000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5636000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5752000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
65417000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61036000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
71053000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66788000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0620
CY2022Q2 us-gaap Lease Cost
LeaseCost
3300000
CY2021Q2 us-gaap Lease Cost
LeaseCost
2700000
us-gaap Lease Cost
LeaseCost
6500000
us-gaap Lease Cost
LeaseCost
5400000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2800000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2500000
us-gaap Operating Lease Payments
OperatingLeasePayments
5500000
us-gaap Operating Lease Payments
OperatingLeasePayments
5000000.0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4524000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11701000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13169000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13437000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13816000
CY2022Q2 ntra Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
34100000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
90747000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19694000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
71053000
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
134016000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
193000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
372000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
376000
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q2 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-145151000
CY2021Q2 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-116026000
ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-283746000
ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-179879000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96579000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88077000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96081000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87387000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21490000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17718000

Files In Submission

Name View Source Status
0001558370-22-012331-index-headers.html Edgar Link pending
0001558370-22-012331-index.html Edgar Link pending
0001558370-22-012331.txt Edgar Link pending
0001558370-22-012331-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20220630.xsd Edgar Link pending
ntra-20220630x10q.htm Edgar Link pending
ntra-20220630x10q_htm.xml Edgar Link completed
ntra-20220630xex10d1.htm Edgar Link pending
ntra-20220630xex31d1.htm Edgar Link pending
ntra-20220630xex31d2.htm Edgar Link pending
ntra-20220630xex32d1.htm Edgar Link pending
ntra-20220630xex32d2.htm Edgar Link pending
ntra-20220630_cal.xml Edgar Link unprocessable
ntra-20220630_def.xml Edgar Link unprocessable
ntra-20220630_lab.xml Edgar Link unprocessable
ntra-20220630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending